Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel, cisplatin, and cetuximab as neoadjuvant induction before surgery in NSCLC
2006-004639-31Phase 2Completed
- Sponsor
- Tako
- Start
- Nov 2006
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab, docetaxel and cisplatin in non-small cell lung cancer (NSCLC), sponsored by Tako. Primary endpoint: surgery. Started Nov 2006; status: completed.
02
Drugs
cetuximabdocetaxelcisplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2006-004639-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004639-31.